Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.biomaterials.2008.04.002
DC FieldValue
dc.titleBiodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma
dc.contributor.authorRanganath, S.H.
dc.contributor.authorWang, C.-H.
dc.date.accessioned2014-10-09T06:43:56Z
dc.date.available2014-10-09T06:43:56Z
dc.date.issued2008-07
dc.identifier.citationRanganath, S.H., Wang, C.-H. (2008-07). Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma. Biomaterials 29 (20) : 2996-3003. ScholarBank@NUS Repository. https://doi.org/10.1016/j.biomaterials.2008.04.002
dc.identifier.issn01429612
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/88581
dc.description.abstractPaclitaxel-loaded biodegradable implants in the form of microfiber discs and sheets were developed using electrospinning technique and investigated against malignant glioma in vitro and in vivo. The fibrous matrices not only provide greater surface area to volume ratio for effective drug release rates but also give the much needed implantability into tumor resected cavity in post-surgical glioma chemotherapy. Poly-(d,l-lactide-co-glycolide) (PLGA) 85:15 co-polymer was used to fabricate microfiber disc (MFD) and microfiber sheet (MFS) and PLGA 50:50 co-polymer was used to fabricate submicrofiber disc (SFD) and submicrofiber sheet (SFS) to avail different drug release properties. All the dosage forms showed sustained paclitaxel release over 80 days in vitro with a small initial burst. Sheets exhibited a relatively higher initial burst compared to discs probably due to the lower compactness. Also, submicrofibers showed higher release against microfiber due to higher surface area to volume ratio and higher degradation rate. Apoptosis study confirmed the advantage of sustained release of paclitaxel from fiber matrices compared to acute Taxol® administration. Animal study confirmed inhibited tumor growth of 75, 78, 69 and 71% for MFD, SFD, MFS and SFS treated groups over placebo control groups after 24 days of tumor growth. Thus these implants may play a crucial role in the local chemotherapy of brain tumors. © 2008 Elsevier Ltd. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.biomaterials.2008.04.002
dc.sourceScopus
dc.subjectDrug delivery
dc.subjectGlioma
dc.subjectIn vivo
dc.subjectMicrofibers
dc.subjectPaclitaxel
dc.subjectPLGA
dc.typeArticle
dc.contributor.departmentCHEMICAL & BIOMOLECULAR ENGINEERING
dc.description.doi10.1016/j.biomaterials.2008.04.002
dc.description.sourcetitleBiomaterials
dc.description.volume29
dc.description.issue20
dc.description.page2996-3003
dc.description.codenBIMAD
dc.identifier.isiut000256655100007
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.